Glenmark Pharmaceuticals Launches Methylene Blue Injection USP in United States Market
Glenmark Pharmaceuticals Inc., USA has announced the launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial. The launch marks a step in strengthening the company's institutional portfolio within the U.S. market.The new product is bioequivalent and therapeutically equivalent to ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL), which is manufactured by Provepharm SAS [NDA 204630].According to IQVIA® sales data for the 12-month period ending April 2026, the market for ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL) recorded annual sales of approximately $19.0 million.The key operational and market details are summarized below...